WO1998056350A1 - Aerosols - Google Patents
Aerosols Download PDFInfo
- Publication number
- WO1998056350A1 WO1998056350A1 PCT/JP1998/002576 JP9802576W WO9856350A1 WO 1998056350 A1 WO1998056350 A1 WO 1998056350A1 JP 9802576 W JP9802576 W JP 9802576W WO 9856350 A1 WO9856350 A1 WO 9856350A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- weight
- aerosol
- parts
- stock solution
- acid
- Prior art date
Links
- 239000000443 aerosol Substances 0.000 title claims abstract description 50
- 238000001816 cooling Methods 0.000 claims abstract description 28
- 239000011550 stock solution Substances 0.000 claims abstract description 26
- 150000002763 monocarboxylic acids Chemical class 0.000 claims abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 11
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 claims description 10
- 235000021355 Stearic acid Nutrition 0.000 claims description 9
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 9
- 239000008117 stearic acid Substances 0.000 claims description 9
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 claims description 6
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 6
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 claims description 5
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 4
- 239000001294 propane Substances 0.000 claims description 4
- 235000021357 Behenic acid Nutrition 0.000 claims description 3
- 235000021314 Palmitic acid Nutrition 0.000 claims description 3
- 229940116226 behenic acid Drugs 0.000 claims description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 3
- 239000005639 Lauric acid Substances 0.000 claims description 2
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 16
- 230000002459 sustained effect Effects 0.000 abstract description 7
- 208000002193 Pain Diseases 0.000 abstract description 5
- 208000003251 Pruritus Diseases 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 5
- 230000036407 pain Effects 0.000 abstract description 5
- 230000007803 itching Effects 0.000 abstract description 3
- 208000034656 Contusions Diseases 0.000 abstract description 2
- 208000006877 Insect Bites and Stings Diseases 0.000 abstract description 2
- 208000010040 Sprains and Strains Diseases 0.000 abstract description 2
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 abstract description 2
- 201000004647 tinea pedis Diseases 0.000 abstract description 2
- 206010024453 Ligament sprain Diseases 0.000 abstract 1
- 150000001298 alcohols Chemical class 0.000 abstract 1
- 208000034526 bruise Diseases 0.000 abstract 1
- 230000003387 muscular Effects 0.000 abstract 1
- 238000005507 spraying Methods 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 12
- 239000007789 gas Substances 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 229940075894 denatured ethanol Drugs 0.000 description 5
- -1 polyoxyethylene cetyl ether Polymers 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940031578 diisopropyl adipate Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 230000035597 cooling sensation Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- MCCACAIVAXEFAL-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 MCCACAIVAXEFAL-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940100608 glycol distearate Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000003915 liquefied petroleum gas Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960005040 miconazole nitrate Drugs 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/046—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/24—Thermal properties
- A61K2800/244—Endothermic; Cooling; Cooling sensation
Definitions
- the present invention relates to an aerosol agent having an enhanced cooling effect by solidifying an ejected substance in a shovel form.
- an aerosol formulation containing a lower alcohol, a linear monocarboxylic acid, and a liquefied gas causes the ejected material to solidify in a shaved manner at the application area.
- the present inventors have found that they have a sustained cooling effect and are also extremely excellent in use feeling, and have completed the present invention.
- the present invention provides a skin cooling solution comprising a stock solution containing a lower alcohol having 1 to 3 carbon atoms and a linear monocarboxylic acid having 10 to 22 carbon atoms and a liquefied gas, in which the ejecta solidifies in a sherbet-like manner at the application site.
- Aerosol preparation Conventionally, in formulation An aerosol for cooling the skin, which exerts a cooling effect by incorporating a linear monocarboxylic acid into the product, has not been known.
- the sheavet shape refers to a state in which a part of the aerosol content is solidified at an application site due to a cooling force that evaporates a liquefied gas when ejected, and specifically, a liquid at an application site. And a state in which solidified products of fine crystals are mixed.
- the lower alcohol is mixed as a liquid and the linear monocarboxylic acid as a coagulated product of fine crystals when jetted, thereby producing a sustained cooling effect.
- the lower alcohol having 1 to 3 carbon atoms is a linear or branched alcohol, and specific examples include methanol, ethanol, denatured ethanol, ethanol, isopropanol, and the like. Particularly preferred are ethanol and isopropanol.
- the blending amount of the lower alcohol is preferably 6 to 99% by weight of the stock solution, more preferably 10 to 95% by weight, and most preferably 30 to 90% by weight. If the blending amount of the lower alcohol is less than 6% by weight of the stock solution, the stock solution and the propellant are difficult to mix uniformly, and if it exceeds 99% by weight, the sustainability of the cooling effect is reduced.
- Preferred examples of the linear monocarboxylic acid having 10 to 22 carbon atoms of the present invention include lauric acid, myristic acid, palmitic acid, stearic acid and behenic acid, and most preferred are Stearic acid can be given.
- the blending amount of the linear monocarboxylic acid is preferably from 1 to 28% by weight of the stock solution, more preferably from 1.5 to 20% by weight, and most preferably from 2 to 15% by weight. If the amount of the linear monocarboxylic acid is less than 1% by weight of the undiluted solution, the ejected material is difficult to coagulate, so that the sustained cooling sensation is weakened. This is because it is difficult to dissolve and the production becomes complicated.
- the liquefied gas may be any one usually used as a propellant in an aerosol, but preferred examples include dimethyl ether, n-butane, i-butane, propane, and liquefied petroleum gas alone or in a mixture. Particularly preferred are dimethyl ether, n-butane and i-butane.
- the amount of the liquefied gas is preferably 0.5 to 20 parts by weight, more preferably 1 to 9 parts by weight, based on 1 part by weight of the stock solution. If the amount of the liquefied gas per 1 part by weight of the undiluted solution is less than 0.5 part by weight, the cooling sensation of the aerosol is reduced, so that the effect of calming pain and itch is weakened, and the amount of the liquefied gas is 20 parts by weight. If the aerosol sprays over the part, the spray property of the aerosol becomes mist-like, and it is difficult to obtain a sustained cooling effect.
- the aerosol of the present invention is prepared by dissolving a lower alcohol and a linear monocarboxylic acid so as to be a homogeneous system and, if necessary, further adding an undiluted component to the aerosol container together with a liquefied gas.
- As the aerosol container a commonly used metal or plastic container can be used. From the viewpoint of maintaining the cooling effect, it is more preferable to mix an appropriate amount of water as another component that does not break the homogeneous system.
- water is blended in the stock solution, it can be blended in an amount of 90% by weight or less of the whole stock solution, but from the viewpoint of easy formulation design, it is preferable to blend 20 to 60% by weight of the stock solution.
- the aerosol of the present invention enhances the effect of calming the pain and itch in the affected area.
- Pharmaceutical ingredients such as keratolytics and fresheners can be added.
- a drug unstable in water and a drug having high lipophilicity can be blended.
- the amount of the medicinal ingredient varies depending on the ingredient, but it is usually 0.001 to 10% by weight of the whole preparation.
- the aerosol of the present invention if necessary, is commonly used in aerosols such as antioxidants, transdermal absorption enhancers, humectants, emulsifiers, gelling agents, adhesives, fragrances, dyes, etc. Can be blended.
- Example 1 Example 1
- a stock solution was prepared by mixing 3.11 parts by weight of stearic acid and 21.41 parts by weight of ethanol.
- the stock solution was filled in a pressure vessel, fitted with a valve, and charged with 0.08 parts by weight of propane, 2.1 parts by weight of n-butane, 1.07 parts by weight of i-butane and 72.22 parts by weight of dimethyl ether.
- An aerosol was obtained.
- Example 2
- Piroxicam 0.18 parts by weight, macrogol 400 1.76 parts by weight, glycerin 0.7 parts by weight, stearic acid 0.53 parts by weight, palmitic acid 0.53 parts by weight, polyoxyethylene stearyl ether 0.7 parts by weight 0.35 parts by weight of polyoxyethylene hydrogenated castor oil, 16.85 parts by weight of denatured ethanol, and 8.74 parts by weight of purified water were mixed and stirred to uniformly dissolve to prepare a stock solution.
- the stock solution was filled in a pressure-resistant container, fitted with a valve, and filled with 69.49 parts by weight of dimethyl ether to obtain an aerosol.
- Example 2 An aerosol was obtained in the same manner as in Example 1 except that the stearic acid in Example 1 was changed to ethanol. Comparative Example 2
- a comparative azol agent was obtained in the same manner as in Example 2, except that the polyoxyethylene cetyl ether of Example 2 was changed to denatured ethanol and the stearate was changed to purified water. Comparative Example 3
- An aerosol was produced in substantially the same manner as the shearbet aerosol described in Example 1 of JP-A-4-103526.
- thermocouple sensor 33 Attach a sheet with thermocouple sensor fixed with tape on a constant temperature water bath set at 33 ° C, and spray the thermosol sensor with the aerosol of Examples 1-3 and Comparative Examples 1-4 for 3 seconds each. did. The properties of the ejecta were confirmed, and the values indicated by the thermocouple sensor were measured over time. Table 1 shows the results.
- ⁇ Indicates that the jet was solidified in a sheavet shape.
- Example 4 and Comparative Example 4 which have relatively close cooling power, a usability test was conducted on 30 subjects. The subjects who had a good feeling of use according to the subject's preference were asked to choose one of the following three options: 1 Example 4, 2 Comparative Example 4, and 3 Neither. The results were (1) 29, (2) 0, and (3) 1 person.
- the aerosol of the present invention is a conventional sherbet-like aerosol. It was confirmed that the feeling of use was superior to that of the cosmetic preparation. Industrial applicability
- the present invention it has become possible to provide an aerosol agent which is extremely excellent in usability and maintains a cooling effect for a long time. Further, according to the present invention, it has become possible to provide an aerosol for cooling skin containing an unstable component or the like in water, which was conventionally difficult to mix.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU76739/98A AU729680B2 (en) | 1997-06-13 | 1998-06-11 | Aerosol preparation |
EP98924576A EP0993827A4 (en) | 1997-06-13 | 1998-06-11 | AEROSOLE |
CA002293622A CA2293622C (en) | 1997-06-13 | 1998-06-11 | Aerosol preparation |
US09/445,563 US6231835B1 (en) | 1997-06-13 | 1998-06-11 | Aerosol preparation for skin cooling |
KR10-1999-7011716A KR100477498B1 (ko) | 1997-06-13 | 1998-06-11 | 에어로졸제 |
HK00107333A HK1027968A1 (en) | 1997-06-13 | 2000-11-17 | Aerosols |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9/156402 | 1997-06-13 | ||
JP15640297 | 1997-06-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998056350A1 true WO1998056350A1 (fr) | 1998-12-17 |
Family
ID=15626964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1998/002576 WO1998056350A1 (fr) | 1997-06-13 | 1998-06-11 | Aerosols |
Country Status (8)
Country | Link |
---|---|
US (1) | US6231835B1 (ja) |
EP (1) | EP0993827A4 (ja) |
KR (1) | KR100477498B1 (ja) |
CN (1) | CN1082366C (ja) |
AU (1) | AU729680B2 (ja) |
CA (1) | CA2293622C (ja) |
HK (1) | HK1027968A1 (ja) |
WO (1) | WO1998056350A1 (ja) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
US8119150B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US20080138296A1 (en) | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
EP1556009B2 (en) | 2002-10-25 | 2021-07-21 | Foamix Pharmaceuticals Ltd. | Cosmetic and pharmaceutical foam |
US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
DE10255285A1 (de) * | 2002-11-26 | 2004-06-03 | Mcs Micro Carrier Systems Gmbh | Selbst formende Phospholipid-Gele |
US7575739B2 (en) | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
US7186416B2 (en) * | 2003-05-28 | 2007-03-06 | Stiefel Laboratories, Inc. | Foamable pharmaceutical compositions and methods for treating a disorder |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
CA2564822A1 (en) * | 2004-04-30 | 2005-11-17 | Burrell E. Clawson | Apparatus and methods for isolating human body areas for localized cooling |
FR2873293B1 (fr) * | 2004-07-21 | 2006-11-17 | Cerep Sa | Utilisation d'un acide gras pour la preparation d'une composition topique destinee a l'apaisement des reactions inflammatoires dues aux piqures d'hymenopteres a venin |
WO2006134013A1 (en) * | 2005-06-14 | 2006-12-21 | Symrise Gmbh & Co. Kg | Mixtures comprising anthranilic acid amides and cooling agents as cosmetic and pharmaceutical compositions for alleviating itching |
US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US9439857B2 (en) | 2007-11-30 | 2016-09-13 | Foamix Pharmaceuticals Ltd. | Foam containing benzoyl peroxide |
WO2010041141A2 (en) | 2008-10-07 | 2010-04-15 | Foamix Ltd. | Oil-based foamable carriers and formulations |
WO2009090495A2 (en) | 2007-12-07 | 2009-07-23 | Foamix Ltd. | Oil and liquid silicone foamable carriers and formulations |
CA2711703A1 (en) * | 2008-01-08 | 2009-07-16 | Foamix Ltd. | Sensation modifying topical composition foam |
EP2242476A2 (en) | 2008-01-14 | 2010-10-27 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
US20120087872A1 (en) | 2009-04-28 | 2012-04-12 | Foamix Ltd. | Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof |
WO2011013009A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
WO2011013008A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
US10029013B2 (en) | 2009-10-02 | 2018-07-24 | Foamix Pharmaceuticals Ltd. | Surfactant-free, water-free formable composition and breakable foams and their uses |
MX2020012139A (es) | 2016-09-08 | 2021-01-29 | Vyne Pharmaceuticals Inc | Composiciones y metodos para tratar rosacea y acne. |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990011068A1 (fr) * | 1989-03-17 | 1990-10-04 | Taisho Pharmaceutical Co., Ltd. | Preparation aerosol a usage externe |
JPH02255890A (ja) * | 1988-12-28 | 1990-10-16 | Osaka Aerosol Ind Corp | エアゾール用組成物 |
JPH04103526A (ja) * | 1990-08-21 | 1992-04-06 | Taisho Pharmaceut Co Ltd | 皮膚冷却エアゾール剤 |
JPH0899868A (ja) * | 1994-10-03 | 1996-04-16 | Chuo Aerosol Kagaku Kk | シャーベット状を形成するエアゾール製品 |
JPH09110677A (ja) * | 1995-08-10 | 1997-04-28 | Taisho Pharmaceut Co Ltd | エアゾール剤 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60222142A (ja) * | 1984-04-20 | 1985-11-06 | Shiseido Co Ltd | 水中油型乳化組成物 |
JP2795351B2 (ja) * | 1989-08-22 | 1998-09-10 | 東洋エアゾール工業株式会社 | 人体用エアゾール組成物 |
AU6531996A (en) | 1995-08-10 | 1997-03-05 | Taisho Pharmaceutical Co., Ltd. | Aerosol preparation |
-
1998
- 1998-06-11 AU AU76739/98A patent/AU729680B2/en not_active Ceased
- 1998-06-11 EP EP98924576A patent/EP0993827A4/en not_active Withdrawn
- 1998-06-11 US US09/445,563 patent/US6231835B1/en not_active Expired - Fee Related
- 1998-06-11 KR KR10-1999-7011716A patent/KR100477498B1/ko not_active IP Right Cessation
- 1998-06-11 CN CN988061716A patent/CN1082366C/zh not_active Expired - Fee Related
- 1998-06-11 CA CA002293622A patent/CA2293622C/en not_active Expired - Fee Related
- 1998-06-11 WO PCT/JP1998/002576 patent/WO1998056350A1/ja active IP Right Grant
-
2000
- 2000-11-17 HK HK00107333A patent/HK1027968A1/xx not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02255890A (ja) * | 1988-12-28 | 1990-10-16 | Osaka Aerosol Ind Corp | エアゾール用組成物 |
WO1990011068A1 (fr) * | 1989-03-17 | 1990-10-04 | Taisho Pharmaceutical Co., Ltd. | Preparation aerosol a usage externe |
JPH04103526A (ja) * | 1990-08-21 | 1992-04-06 | Taisho Pharmaceut Co Ltd | 皮膚冷却エアゾール剤 |
JPH0899868A (ja) * | 1994-10-03 | 1996-04-16 | Chuo Aerosol Kagaku Kk | シャーベット状を形成するエアゾール製品 |
JPH09110677A (ja) * | 1995-08-10 | 1997-04-28 | Taisho Pharmaceut Co Ltd | エアゾール剤 |
Non-Patent Citations (1)
Title |
---|
See also references of EP0993827A4 * |
Also Published As
Publication number | Publication date |
---|---|
AU7673998A (en) | 1998-12-30 |
CN1082366C (zh) | 2002-04-10 |
KR20010013701A (ko) | 2001-02-26 |
EP0993827A4 (en) | 2006-07-05 |
HK1027968A1 (en) | 2001-02-02 |
CN1260712A (zh) | 2000-07-19 |
CA2293622A1 (en) | 1998-12-17 |
KR100477498B1 (ko) | 2005-03-18 |
CA2293622C (en) | 2007-08-21 |
US6231835B1 (en) | 2001-05-15 |
AU729680B2 (en) | 2001-02-08 |
EP0993827A1 (en) | 2000-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998056350A1 (fr) | Aerosols | |
WO1997021426A1 (fr) | Preparation aerosol | |
JP2903708B2 (ja) | 外用エアゾール剤 | |
JPS63119420A (ja) | 泡状エアゾ−ル消炎鎮痛製剤 | |
JPH06329532A (ja) | 油中水型エアゾール組成物およびその製法 | |
US20190282464A1 (en) | Whipped formulations | |
JPH0840899A (ja) | 硝酸オキシコナゾールのエアゾール剤 | |
JP3302995B2 (ja) | エアゾール組成物 | |
JP5044103B2 (ja) | 乳化型エアゾール組成物 | |
JP4353381B2 (ja) | エアゾール剤 | |
JP3027838B2 (ja) | エヤゾール組成物 | |
JP3658897B2 (ja) | エアゾール剤 | |
JPS6231975B2 (ja) | ||
JP2634858B2 (ja) | 速破性発泡エアゾール組成物 | |
JP3862076B2 (ja) | 後発泡性パック料 | |
JP5507818B2 (ja) | エアゾール組成物 | |
JP5341397B2 (ja) | エアゾール組成物 | |
JP4176859B2 (ja) | エアゾール製剤 | |
JP4458560B2 (ja) | エアゾール剤 | |
JP4451625B2 (ja) | 噴霧用エアゾール組成物 | |
JP4812952B2 (ja) | エアゾール組成物 | |
JPH10139658A (ja) | 皮膚冷却エアゾール剤 | |
JPH09157638A (ja) | 人体用エアゾール組成物 | |
JPH072944B2 (ja) | 冷却用エアゾ−ル組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 98806171.6 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2293622 Country of ref document: CA Ref document number: 2293622 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09445563 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019997011716 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998924576 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 76739/98 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1998924576 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997011716 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 76739/98 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1019997011716 Country of ref document: KR |